Nicola Personeni
Overview
Explore the profile of Nicola Personeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
2623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macagno M, Pessei V, Congiusta N, Lazzari L, Bellomo S, Idrees F, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594133
is responsible for the direct repair of O6-methylguanine lesions induced by alkylating agents, including temozolomide. promoter hypermethylation is a well-established biomarker for temozolomide response in glioblastoma patients, also correlated with...
2.
Prinzi F, Salani F, Rimini M, Rizzato M, Antonuzzo L, Camera S, et al.
Oncologist
. 2024 Oct;
PMID: 39427227
Background: In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our...
3.
Rimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, et al.
Eur J Cancer
. 2024 Jul;
208:114199.
PMID: 39002348
Background: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy...
4.
Dharmapuri S, Ozbek U, Jethra H, Jun T, Marron T, Saeed A, et al.
World J Gastrointest Oncol
. 2023 Dec;
15(11):1900-1912.
PMID: 38077640
Background: A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI....
5.
Talbot T, DAlessio A, Pinter M, Balcar L, Scheiner B, Marron T, et al.
Liver Int
. 2022 Dec;
43(3):695-707.
PMID: 36577703
Background And Aims: Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including the continuation of ICI, treatment switching to...
6.
Wu Y, Fulgenzi C, DAlessio A, Cheon J, Nishida N, Saeed A, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497316
Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic...
7.
Personeni N, Pressiani T, Zanuso V, Casadei-Gardini A, DAlessio A, Valgiusti M, et al.
J Pers Med
. 2022 Oct;
12(10).
PMID: 36294865
Second-line treatments are standard care for advanced hepatocellular carcinoma (HCC) patients with preserved liver function who are intolerant of or progress on first-line therapy. However, determinants of treatment benefit and...
8.
Fulgenzi C, Cheon J, DAlessio A, Nishida N, Ang C, Marron T, et al.
Eur J Cancer
. 2022 Sep;
175:204-213.
PMID: 36148739
Background: IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods: We generated a prospectively maintained database including patients treated with...
9.
Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L
J Hepatocell Carcinoma
. 2022 Sep;
9:1011-1027.
PMID: 36128575
Advanced hepatocellular carcinoma (HCC) management has become more complex as novel therapies have been proven effective. After sorafenib, the approval of other multikinase inhibitors (MKIs) and immune checkpoints inhibitors (ICIs)...
10.
Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Lavacchi D, et al.
Target Oncol
. 2022 Sep;
17(5):591-596.
PMID: 36114954
Background: The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA)...